The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study
Identifieur interne : 001318 ( Main/Corpus ); précédent : 001317; suivant : 001319The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study
Auteurs : Kallol Ray Chaudhuri ; Pablo Martinez-Martin ; Richard G. Brown ; Kapil Sethi ; Fabrizio Stocchi ; Per Odin ; William Ondo ; Kazuo Abe ; Graeme Macphee ; Doug Macmahon ; Paolo Barone ; Martin Rabey ; Alison Forbes ; Kieran Breen ; Susanne Tluk ; Yogini Naidu ; Warren Olanow ; Adrian J. Williams ; Sue Thomas ; David Rye ; Yoshio Tsuboi ; Annette Hand ; Anthony H. V. SchapiraSource :
- Movement Disorders [ 0885-3185 ] ; 2007-10-15.
English descriptors
- KwdEn :
Abstract
Non‐motor symptoms (NMS) in Parkinson's disease (PD) are common, significantly reduce quality of life and at present there is no validated clinical tool to assess the progress or potential response to treatment of NMS. A new 30‐item scale for the assessment of NMS in PD (NMSS) was developed. NMSS contains nine dimensions: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems, attention/memory, gastrointestinal, urinary, sexual function, and miscellany. The metric attributes of this instrument were analyzed. Data from 242 patients mean age 67.2 ± 11 years, duration of disease 6.4 ± 6 years, and 57.3% male across all stages of PD were collected from the centers in Europe, USA, and Japan. The mean NMSS score was 56.5 ± 40.7, (range: 0–243) and only one declared no NMS. The scale provided 99.2% complete data for the analysis with the total score being free of floor and ceiling effect. Satisfactory scaling assumptions (multitrait scaling success rate >95% for all domains except miscellany) and internal consistency were reported for most of the domains (mean α, 0.61). Factor analysis supported the a prori nine domain structure (63% of the variance) while a small test–retest study showed satisfactory reproducibility (ICC > 0.80) for all domains except cardiovascular (ICC = 0.45). In terms of validity, the scale showed modest association with indicators of motor symptom severity and disease progression but a high correlation with other measures of NMS (NMSQuest) and health‐related quality of life measure (PDQ‐8) (both, rS = 0.70). In conclusion, NMSS can be used to assess the frequency and severity of NMS in PD patients across all stages in conjunction with the recently validated non‐motor questionnaire. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21596
Links to Exploration step
ISTEX:0B767526089E03D8DB1524ADD54446FEA89E3A74Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study</title><author><name sortKey="Chaudhuri, Kallol Ray" sort="Chaudhuri, Kallol Ray" uniqKey="Chaudhuri K" first="Kallol Ray" last="Chaudhuri">Kallol Ray Chaudhuri</name><affiliation><mods:affiliation>National Parkinson Foundation Centre of Excellence, Kings College Hospital, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University Hospital Lewisham, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>Kings College, Institute of Psychiatry, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation><mods:affiliation>Unit of Neuroepidemiology, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Brown, Richard G" sort="Brown, Richard G" uniqKey="Brown R" first="Richard G." last="Brown">Richard G. Brown</name><affiliation><mods:affiliation>Department of Psychology, Institute of Psychiatry, King's College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Sethi, Kapil" sort="Sethi, Kapil" uniqKey="Sethi K" first="Kapil" last="Sethi">Kapil Sethi</name><affiliation><mods:affiliation>Department of Neurology, Medical College of Georgia, USA</mods:affiliation></affiliation></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name><affiliation><mods:affiliation>Department of Neurology, IRCCS San Raffaele, Pisana, Roma, Italy</mods:affiliation></affiliation></author><author><name sortKey="Odin, Per" sort="Odin, Per" uniqKey="Odin P" first="Per" last="Odin">Per Odin</name><affiliation><mods:affiliation>Department of Neurology, Klinikum‐Bremerhaven Reinkenheide, Bremerhaven, Germany</mods:affiliation></affiliation></author><author><name sortKey="Ondo, William" sort="Ondo, William" uniqKey="Ondo W" first="William" last="Ondo">William Ondo</name><affiliation><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Abe, Kazuo" sort="Abe, Kazuo" uniqKey="Abe K" first="Kazuo" last="Abe">Kazuo Abe</name><affiliation><mods:affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Macphee, Graeme" sort="Macphee, Graeme" uniqKey="Macphee G" first="Graeme" last="Macphee">Graeme Macphee</name><affiliation><mods:affiliation>Medicine for the Elderly, Southern General Hospital, Glasgow, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Macmahon, Doug" sort="Macmahon, Doug" uniqKey="Macmahon D" first="Doug" last="Macmahon">Doug Macmahon</name><affiliation><mods:affiliation>Medicine for Care of Elderly, Camborne‐Redruth Hospital, Redruth, Cornwall, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name><affiliation><mods:affiliation>Department of Neurological Sciences, University of Napoli, Napoli, Italy</mods:affiliation></affiliation></author><author><name sortKey="Rabey, Martin" sort="Rabey, Martin" uniqKey="Rabey M" first="Martin" last="Rabey">Martin Rabey</name><affiliation><mods:affiliation>Department of Neurology, Assaf Harofeh Medical Center, School of Medicine, Tel‐Aviv University, Zerifin, Israel</mods:affiliation></affiliation></author><author><name sortKey="Forbes, Alison" sort="Forbes, Alison" uniqKey="Forbes A" first="Alison" last="Forbes">Alison Forbes</name><affiliation><mods:affiliation>National Parkinson Foundation Centre of Excellence, Kings College Hospital, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Breen, Kieran" sort="Breen, Kieran" uniqKey="Breen K" first="Kieran" last="Breen">Kieran Breen</name><affiliation><mods:affiliation>Research and Development Department, The UK Parkinson's Disease Society, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Tluk, Susanne" sort="Tluk, Susanne" uniqKey="Tluk S" first="Susanne" last="Tluk">Susanne Tluk</name><affiliation><mods:affiliation>Department of Neurology, University Hospital Lewisham, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Naidu, Yogini" sort="Naidu, Yogini" uniqKey="Naidu Y" first="Yogini" last="Naidu">Yogini Naidu</name><affiliation><mods:affiliation>Department of Neurology, University Hospital Lewisham, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Olanow, Warren" sort="Olanow, Warren" uniqKey="Olanow W" first="Warren" last="Olanow">Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, The Mount Sinai School of Medicine, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Williams, Adrian J" sort="Williams, Adrian J" uniqKey="Williams A" first="Adrian J." last="Williams">Adrian J. Williams</name><affiliation><mods:affiliation>Lane Fox Sleep Centre, St. Thomas' Hospital, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Thomas, Sue" sort="Thomas, Sue" uniqKey="Thomas S" first="Sue" last="Thomas">Sue Thomas</name><affiliation><mods:affiliation>Policy Advice, Royal College of Nursing, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Rye, David" sort="Rye, David" uniqKey="Rye D" first="David" last="Rye">David Rye</name><affiliation><mods:affiliation>Department of Neurology, Emory University, Atlanta, Georgia, USA</mods:affiliation></affiliation></author><author><name sortKey="Tsuboi, Yoshio" sort="Tsuboi, Yoshio" uniqKey="Tsuboi Y" first="Yoshio" last="Tsuboi">Yoshio Tsuboi</name><affiliation><mods:affiliation>Fifth Department of Internal Medicine, Fukuoka University, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Hand, Annette" sort="Hand, Annette" uniqKey="Hand A" first="Annette" last="Hand">Annette Hand</name><affiliation><mods:affiliation>Department of Medicine, North Tyneside General Hospital, North Shields, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name><affiliation><mods:affiliation>Department of Clinical Neuroscience, Royal Free Hospital Medical School, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>National Hospital for Neurology and Neurosurgery, London, United Kingdom</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0B767526089E03D8DB1524ADD54446FEA89E3A74</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21596</idno><idno type="url">https://api.istex.fr/document/0B767526089E03D8DB1524ADD54446FEA89E3A74/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001318</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study</title><author><name sortKey="Chaudhuri, Kallol Ray" sort="Chaudhuri, Kallol Ray" uniqKey="Chaudhuri K" first="Kallol Ray" last="Chaudhuri">Kallol Ray Chaudhuri</name><affiliation><mods:affiliation>National Parkinson Foundation Centre of Excellence, Kings College Hospital, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, University Hospital Lewisham, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>Kings College, Institute of Psychiatry, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation><mods:affiliation>Unit of Neuroepidemiology, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Brown, Richard G" sort="Brown, Richard G" uniqKey="Brown R" first="Richard G." last="Brown">Richard G. Brown</name><affiliation><mods:affiliation>Department of Psychology, Institute of Psychiatry, King's College London, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Sethi, Kapil" sort="Sethi, Kapil" uniqKey="Sethi K" first="Kapil" last="Sethi">Kapil Sethi</name><affiliation><mods:affiliation>Department of Neurology, Medical College of Georgia, USA</mods:affiliation></affiliation></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name><affiliation><mods:affiliation>Department of Neurology, IRCCS San Raffaele, Pisana, Roma, Italy</mods:affiliation></affiliation></author><author><name sortKey="Odin, Per" sort="Odin, Per" uniqKey="Odin P" first="Per" last="Odin">Per Odin</name><affiliation><mods:affiliation>Department of Neurology, Klinikum‐Bremerhaven Reinkenheide, Bremerhaven, Germany</mods:affiliation></affiliation></author><author><name sortKey="Ondo, William" sort="Ondo, William" uniqKey="Ondo W" first="William" last="Ondo">William Ondo</name><affiliation><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</mods:affiliation></affiliation></author><author><name sortKey="Abe, Kazuo" sort="Abe, Kazuo" uniqKey="Abe K" first="Kazuo" last="Abe">Kazuo Abe</name><affiliation><mods:affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Macphee, Graeme" sort="Macphee, Graeme" uniqKey="Macphee G" first="Graeme" last="Macphee">Graeme Macphee</name><affiliation><mods:affiliation>Medicine for the Elderly, Southern General Hospital, Glasgow, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Macmahon, Doug" sort="Macmahon, Doug" uniqKey="Macmahon D" first="Doug" last="Macmahon">Doug Macmahon</name><affiliation><mods:affiliation>Medicine for Care of Elderly, Camborne‐Redruth Hospital, Redruth, Cornwall, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name><affiliation><mods:affiliation>Department of Neurological Sciences, University of Napoli, Napoli, Italy</mods:affiliation></affiliation></author><author><name sortKey="Rabey, Martin" sort="Rabey, Martin" uniqKey="Rabey M" first="Martin" last="Rabey">Martin Rabey</name><affiliation><mods:affiliation>Department of Neurology, Assaf Harofeh Medical Center, School of Medicine, Tel‐Aviv University, Zerifin, Israel</mods:affiliation></affiliation></author><author><name sortKey="Forbes, Alison" sort="Forbes, Alison" uniqKey="Forbes A" first="Alison" last="Forbes">Alison Forbes</name><affiliation><mods:affiliation>National Parkinson Foundation Centre of Excellence, Kings College Hospital, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Breen, Kieran" sort="Breen, Kieran" uniqKey="Breen K" first="Kieran" last="Breen">Kieran Breen</name><affiliation><mods:affiliation>Research and Development Department, The UK Parkinson's Disease Society, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Tluk, Susanne" sort="Tluk, Susanne" uniqKey="Tluk S" first="Susanne" last="Tluk">Susanne Tluk</name><affiliation><mods:affiliation>Department of Neurology, University Hospital Lewisham, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Naidu, Yogini" sort="Naidu, Yogini" uniqKey="Naidu Y" first="Yogini" last="Naidu">Yogini Naidu</name><affiliation><mods:affiliation>Department of Neurology, University Hospital Lewisham, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Olanow, Warren" sort="Olanow, Warren" uniqKey="Olanow W" first="Warren" last="Olanow">Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology, The Mount Sinai School of Medicine, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Williams, Adrian J" sort="Williams, Adrian J" uniqKey="Williams A" first="Adrian J." last="Williams">Adrian J. Williams</name><affiliation><mods:affiliation>Lane Fox Sleep Centre, St. Thomas' Hospital, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Thomas, Sue" sort="Thomas, Sue" uniqKey="Thomas S" first="Sue" last="Thomas">Sue Thomas</name><affiliation><mods:affiliation>Policy Advice, Royal College of Nursing, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Rye, David" sort="Rye, David" uniqKey="Rye D" first="David" last="Rye">David Rye</name><affiliation><mods:affiliation>Department of Neurology, Emory University, Atlanta, Georgia, USA</mods:affiliation></affiliation></author><author><name sortKey="Tsuboi, Yoshio" sort="Tsuboi, Yoshio" uniqKey="Tsuboi Y" first="Yoshio" last="Tsuboi">Yoshio Tsuboi</name><affiliation><mods:affiliation>Fifth Department of Internal Medicine, Fukuoka University, Fukuoka, Japan</mods:affiliation></affiliation></author><author><name sortKey="Hand, Annette" sort="Hand, Annette" uniqKey="Hand A" first="Annette" last="Hand">Annette Hand</name><affiliation><mods:affiliation>Department of Medicine, North Tyneside General Hospital, North Shields, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name><affiliation><mods:affiliation>Department of Clinical Neuroscience, Royal Free Hospital Medical School, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>National Hospital for Neurology and Neurosurgery, London, United Kingdom</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-10-15">2007-10-15</date><biblScope unit="volume">22</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="1901">1901</biblScope><biblScope unit="page" to="1911">1911</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">0B767526089E03D8DB1524ADD54446FEA89E3A74</idno><idno type="DOI">10.1002/mds.21596</idno><idno type="ArticleID">MDS21596</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>PD</term><term>UPDRS</term><term>non‐motor</term><term>quality of life</term><term>questionnaire</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Non‐motor symptoms (NMS) in Parkinson's disease (PD) are common, significantly reduce quality of life and at present there is no validated clinical tool to assess the progress or potential response to treatment of NMS. A new 30‐item scale for the assessment of NMS in PD (NMSS) was developed. NMSS contains nine dimensions: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems, attention/memory, gastrointestinal, urinary, sexual function, and miscellany. The metric attributes of this instrument were analyzed. Data from 242 patients mean age 67.2 ± 11 years, duration of disease 6.4 ± 6 years, and 57.3% male across all stages of PD were collected from the centers in Europe, USA, and Japan. The mean NMSS score was 56.5 ± 40.7, (range: 0–243) and only one declared no NMS. The scale provided 99.2% complete data for the analysis with the total score being free of floor and ceiling effect. Satisfactory scaling assumptions (multitrait scaling success rate >95% for all domains except miscellany) and internal consistency were reported for most of the domains (mean α, 0.61). Factor analysis supported the a prori nine domain structure (63% of the variance) while a small test–retest study showed satisfactory reproducibility (ICC > 0.80) for all domains except cardiovascular (ICC = 0.45). In terms of validity, the scale showed modest association with indicators of motor symptom severity and disease progression but a high correlation with other measures of NMS (NMSQuest) and health‐related quality of life measure (PDQ‐8) (both, rS = 0.70). In conclusion, NMSS can be used to assess the frequency and severity of NMS in PD patients across all stages in conjunction with the recently validated non‐motor questionnaire. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Kallol Ray Chaudhuri</name><affiliations><json:string>National Parkinson Foundation Centre of Excellence, Kings College Hospital, London, United Kingdom</json:string><json:string>Department of Neurology, University Hospital Lewisham, London, United Kingdom</json:string><json:string>Kings College, Institute of Psychiatry, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Pablo Martinez‐Martin</name><affiliations><json:string>Unit of Neuroepidemiology, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain</json:string></affiliations></json:item><json:item><name>Richard G. Brown</name><affiliations><json:string>Department of Psychology, Institute of Psychiatry, King's College London, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Kapil Sethi</name><affiliations><json:string>Department of Neurology, Medical College of Georgia, USA</json:string></affiliations></json:item><json:item><name>Fabrizio Stocchi</name><affiliations><json:string>Department of Neurology, IRCCS San Raffaele, Pisana, Roma, Italy</json:string></affiliations></json:item><json:item><name>Per Odin</name><affiliations><json:string>Department of Neurology, Klinikum‐Bremerhaven Reinkenheide, Bremerhaven, Germany</json:string></affiliations></json:item><json:item><name>William Ondo</name><affiliations><json:string>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</json:string></affiliations></json:item><json:item><name>Kazuo Abe</name><affiliations><json:string>Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan</json:string></affiliations></json:item><json:item><name>Graeme MacPhee</name><affiliations><json:string>Medicine for the Elderly, Southern General Hospital, Glasgow, United Kingdom</json:string></affiliations></json:item><json:item><name>Doug MacMahon</name><affiliations><json:string>Medicine for Care of Elderly, Camborne‐Redruth Hospital, Redruth, Cornwall, United Kingdom</json:string></affiliations></json:item><json:item><name>Paolo Barone</name><affiliations><json:string>Department of Neurological Sciences, University of Napoli, Napoli, Italy</json:string></affiliations></json:item><json:item><name>Martin Rabey</name><affiliations><json:string>Department of Neurology, Assaf Harofeh Medical Center, School of Medicine, Tel‐Aviv University, Zerifin, Israel</json:string></affiliations></json:item><json:item><name>Alison Forbes</name><affiliations><json:string>National Parkinson Foundation Centre of Excellence, Kings College Hospital, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Kieran Breen</name><affiliations><json:string>Research and Development Department, The UK Parkinson's Disease Society, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Susanne Tluk</name><affiliations><json:string>Department of Neurology, University Hospital Lewisham, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Yogini Naidu</name><affiliations><json:string>Department of Neurology, University Hospital Lewisham, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Warren Olanow</name><affiliations><json:string>Department of Neurology, The Mount Sinai School of Medicine, New York, USA</json:string></affiliations></json:item><json:item><name>Adrian J. Williams</name><affiliations><json:string>Lane Fox Sleep Centre, St. Thomas' Hospital, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Sue Thomas</name><affiliations><json:string>Policy Advice, Royal College of Nursing, London, United Kingdom</json:string></affiliations></json:item><json:item><name>David Rye</name><affiliations><json:string>Department of Neurology, Emory University, Atlanta, Georgia, USA</json:string></affiliations></json:item><json:item><name>Yoshio Tsuboi</name><affiliations><json:string>Fifth Department of Internal Medicine, Fukuoka University, Fukuoka, Japan</json:string></affiliations></json:item><json:item><name>Annette Hand</name><affiliations><json:string>Department of Medicine, North Tyneside General Hospital, North Shields, United Kingdom</json:string></affiliations></json:item><json:item><name>Anthony H.V. Schapira</name><affiliations><json:string>Department of Clinical Neuroscience, Royal Free Hospital Medical School, London, United Kingdom</json:string><json:string>National Hospital for Neurology and Neurosurgery, London, United Kingdom</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>PD</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>non‐motor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>UPDRS</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>questionnaire</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>quality of life</value></json:item></subject><articleId><json:string>MDS21596</json:string></articleId><language><json:string>eng</json:string></language><abstract>Non‐motor symptoms (NMS) in Parkinson's disease (PD) are common, significantly reduce quality of life and at present there is no validated clinical tool to assess the progress or potential response to treatment of NMS. A new 30‐item scale for the assessment of NMS in PD (NMSS) was developed. NMSS contains nine dimensions: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems, attention/memory, gastrointestinal, urinary, sexual function, and miscellany. The metric attributes of this instrument were analyzed. Data from 242 patients mean age 67.2 ± 11 years, duration of disease 6.4 ± 6 years, and 57.3% male across all stages of PD were collected from the centers in Europe, USA, and Japan. The mean NMSS score was 56.5 ± 40.7, (range: 0–243) and only one declared no NMS. The scale provided 99.2% complete data for the analysis with the total score being free of floor and ceiling effect. Satisfactory scaling assumptions (multitrait scaling success rate >95% for all domains except miscellany) and internal consistency were reported for most of the domains (mean α, 0.61). Factor analysis supported the a prori nine domain structure (63% of the variance) while a small test–retest study showed satisfactory reproducibility (ICC > 0.80) for all domains except cardiovascular (ICC = 0.45). In terms of validity, the scale showed modest association with indicators of motor symptom severity and disease progression but a high correlation with other measures of NMS (NMSQuest) and health‐related quality of life measure (PDQ‐8) (both, rS = 0.70). In conclusion, NMSS can be used to assess the frequency and severity of NMS in PD patients across all stages in conjunction with the recently validated non‐motor questionnaire. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1771</abstractCharCount><pdfWordCount>5826</pdfWordCount><pdfCharCount>38151</pdfCharCount><pdfPageCount>11</pdfPageCount><abstractWordCount>273</abstractWordCount></qualityIndicators><title>The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study</title><genre><json:string>article</json:string></genre><host><volume>22</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>11</total><last>1911</last><first>1901</first></pages><issn><json:string>0885-3185</json:string></issn><issue>13</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21596</json:string></doi><id>0B767526089E03D8DB1524ADD54446FEA89E3A74</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/0B767526089E03D8DB1524ADD54446FEA89E3A74/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/0B767526089E03D8DB1524ADD54446FEA89E3A74/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/0B767526089E03D8DB1524ADD54446FEA89E3A74/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2007</date></publicationStmt><notesStmt><note>PDNMG</note><note>UK Parkinson's Disease Society</note><note>Pfizer</note><note>GSK</note><note>Boehringer‐Ingelheim</note><note>Britannia Pharamaceuticals</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study</title><author><persName><forename type="first">Kallol Ray</forename><surname>Chaudhuri</surname></persName><note type="correspondence"><p>Correspondence: NPF Centre of Excellence, Movement Disorders Unit, 9th Floor Ruskin Wing, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom</p></note><affiliation>National Parkinson Foundation Centre of Excellence, Kings College Hospital, London, United Kingdom</affiliation><affiliation>Department of Neurology, University Hospital Lewisham, London, United Kingdom</affiliation><affiliation>Kings College, Institute of Psychiatry, London, United Kingdom</affiliation></author><author><persName><forename type="first">Pablo</forename><surname>Martinez‐Martin</surname></persName><affiliation>Unit of Neuroepidemiology, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain</affiliation></author><author><persName><forename type="first">Richard G.</forename><surname>Brown</surname></persName><affiliation>Department of Psychology, Institute of Psychiatry, King's College London, London, United Kingdom</affiliation></author><author><persName><forename type="first">Kapil</forename><surname>Sethi</surname></persName><affiliation>Department of Neurology, Medical College of Georgia, USA</affiliation></author><author><persName><forename type="first">Fabrizio</forename><surname>Stocchi</surname></persName><affiliation>Department of Neurology, IRCCS San Raffaele, Pisana, Roma, Italy</affiliation></author><author><persName><forename type="first">Per</forename><surname>Odin</surname></persName><affiliation>Department of Neurology, Klinikum‐Bremerhaven Reinkenheide, Bremerhaven, Germany</affiliation></author><author><persName><forename type="first">William</forename><surname>Ondo</surname></persName><affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</affiliation></author><author><persName><forename type="first">Kazuo</forename><surname>Abe</surname></persName><affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan</affiliation></author><author><persName><forename type="first">Graeme</forename><surname>MacPhee</surname></persName><affiliation>Medicine for the Elderly, Southern General Hospital, Glasgow, United Kingdom</affiliation></author><author><persName><forename type="first">Doug</forename><surname>MacMahon</surname></persName><affiliation>Medicine for Care of Elderly, Camborne‐Redruth Hospital, Redruth, Cornwall, United Kingdom</affiliation></author><author><persName><forename type="first">Paolo</forename><surname>Barone</surname></persName><affiliation>Department of Neurological Sciences, University of Napoli, Napoli, Italy</affiliation></author><author><persName><forename type="first">Martin</forename><surname>Rabey</surname></persName><affiliation>Department of Neurology, Assaf Harofeh Medical Center, School of Medicine, Tel‐Aviv University, Zerifin, Israel</affiliation></author><author><persName><forename type="first">Alison</forename><surname>Forbes</surname></persName><affiliation>National Parkinson Foundation Centre of Excellence, Kings College Hospital, London, United Kingdom</affiliation></author><author><persName><forename type="first">Kieran</forename><surname>Breen</surname></persName><affiliation>Research and Development Department, The UK Parkinson's Disease Society, London, United Kingdom</affiliation></author><author><persName><forename type="first">Susanne</forename><surname>Tluk</surname></persName><affiliation>Department of Neurology, University Hospital Lewisham, London, United Kingdom</affiliation></author><author><persName><forename type="first">Yogini</forename><surname>Naidu</surname></persName><affiliation>Department of Neurology, University Hospital Lewisham, London, United Kingdom</affiliation></author><author><persName><forename type="first">Warren</forename><surname>Olanow</surname></persName><affiliation>Department of Neurology, The Mount Sinai School of Medicine, New York, USA</affiliation></author><author><persName><forename type="first">Adrian J.</forename><surname>Williams</surname></persName><affiliation>Lane Fox Sleep Centre, St. Thomas' Hospital, London, United Kingdom</affiliation></author><author><persName><forename type="first">Sue</forename><surname>Thomas</surname></persName><affiliation>Policy Advice, Royal College of Nursing, London, United Kingdom</affiliation></author><author><persName><forename type="first">David</forename><surname>Rye</surname></persName><affiliation>Department of Neurology, Emory University, Atlanta, Georgia, USA</affiliation></author><author><persName><forename type="first">Yoshio</forename><surname>Tsuboi</surname></persName><affiliation>Fifth Department of Internal Medicine, Fukuoka University, Fukuoka, Japan</affiliation></author><author><persName><forename type="first">Annette</forename><surname>Hand</surname></persName><affiliation>Department of Medicine, North Tyneside General Hospital, North Shields, United Kingdom</affiliation></author><author><persName><forename type="first">Anthony H.V.</forename><surname>Schapira</surname></persName><affiliation>Department of Clinical Neuroscience, Royal Free Hospital Medical School, London, United Kingdom</affiliation><affiliation>National Hospital for Neurology and Neurosurgery, London, United Kingdom</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-10-15"></date><biblScope unit="volume">22</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="1901">1901</biblScope><biblScope unit="page" to="1911">1911</biblScope></imprint></monogr><idno type="istex">0B767526089E03D8DB1524ADD54446FEA89E3A74</idno><idno type="DOI">10.1002/mds.21596</idno><idno type="ArticleID">MDS21596</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Non‐motor symptoms (NMS) in Parkinson's disease (PD) are common, significantly reduce quality of life and at present there is no validated clinical tool to assess the progress or potential response to treatment of NMS. A new 30‐item scale for the assessment of NMS in PD (NMSS) was developed. NMSS contains nine dimensions: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems, attention/memory, gastrointestinal, urinary, sexual function, and miscellany. The metric attributes of this instrument were analyzed. Data from 242 patients mean age 67.2 ± 11 years, duration of disease 6.4 ± 6 years, and 57.3% male across all stages of PD were collected from the centers in Europe, USA, and Japan. The mean NMSS score was 56.5 ± 40.7, (range: 0–243) and only one declared no NMS. The scale provided 99.2% complete data for the analysis with the total score being free of floor and ceiling effect. Satisfactory scaling assumptions (multitrait scaling success rate >95% for all domains except miscellany) and internal consistency were reported for most of the domains (mean α, 0.61). Factor analysis supported the a prori nine domain structure (63% of the variance) while a small test–retest study showed satisfactory reproducibility (ICC > 0.80) for all domains except cardiovascular (ICC = 0.45). In terms of validity, the scale showed modest association with indicators of motor symptom severity and disease progression but a high correlation with other measures of NMS (NMSQuest) and health‐related quality of life measure (PDQ‐8) (both, rS = 0.70). In conclusion, NMSS can be used to assess the frequency and severity of NMS in PD patients across all stages in conjunction with the recently validated non‐motor questionnaire. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>PD</term></item><item><term>non‐motor</term></item><item><term>UPDRS</term></item><item><term>questionnaire</term></item><item><term>quality of life</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-03-06">Received</change><change when="2007-04-24">Registration</change><change when="2007-10-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/0B767526089E03D8DB1524ADD54446FEA89E3A74/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="130"><doi origin="wiley" registered="yes">10.1002/mds.v22:13</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">13</numbering></numberingGroup><coverDate startDate="2007-10-15">15 October 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="100" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21596</doi><idGroup><id type="unit" value="MDS21596"></id></idGroup><countGroup><count type="pageTotal" number="11"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-03-06"></event><event type="manuscriptRevised" date="2007-04-23"></event><event type="manuscriptAccepted" date="2007-04-24"></event><event type="firstOnline" date="2007-08-02"></event><event type="publishedOnlineFinalForm" date="2007-10-26"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2007-08-02"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1901</numbering><numbering type="pageLast">1911</numbering></numberingGroup><correspondenceTo>NPF Centre of Excellence, Movement Disorders Unit, 9th Floor Ruskin Wing, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21596.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="5"></count><count type="referenceTotal" number="46"></count><count type="wordTotal" number="6780"></count></countGroup><titleGroup><title type="main" xml:lang="en">The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study</title><title type="short" xml:lang="en">Non‐Motor Symptoms and PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2 #af3" corresponding="yes"><personName><givenNames>Kallol Ray</givenNames><familyName>Chaudhuri</familyName></personName><contactDetails><email>ray.chaudhuri@uhl.nhs.uk</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Pablo</givenNames><familyName>Martinez‐Martin</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Richard G.</givenNames><familyName>Brown</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Kapil</givenNames><familyName>Sethi</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Fabrizio</givenNames><familyName>Stocchi</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Per</givenNames><familyName>Odin</familyName></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af9"><personName><givenNames>William</givenNames><familyName>Ondo</familyName></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af10"><personName><givenNames>Kazuo</givenNames><familyName>Abe</familyName></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af11"><personName><givenNames>Graeme</givenNames><familyName>MacPhee</familyName></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af12"><personName><givenNames>Doug</givenNames><familyName>MacMahon</familyName></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af13"><personName><givenNames>Paolo</givenNames><familyName>Barone</familyName></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af14"><personName><givenNames>Martin</givenNames><familyName>Rabey</familyName></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Alison</givenNames><familyName>Forbes</familyName></personName></creator><creator xml:id="au14" creatorRole="author" affiliationRef="#af15"><personName><givenNames>Kieran</givenNames><familyName>Breen</familyName></personName></creator><creator xml:id="au15" creatorRole="author" affiliationRef="#af16"><personName><givenNames>Susanne</givenNames><familyName>Tluk</familyName></personName></creator><creator xml:id="au16" creatorRole="author" affiliationRef="#af16"><personName><givenNames>Yogini</givenNames><familyName>Naidu</familyName></personName></creator><creator xml:id="au17" creatorRole="author" affiliationRef="#af17"><personName><givenNames>Warren</givenNames><familyName>Olanow</familyName></personName></creator><creator xml:id="au18" creatorRole="author" affiliationRef="#af18"><personName><givenNames>Adrian J.</givenNames><familyName>Williams</familyName></personName></creator><creator xml:id="au19" creatorRole="author" affiliationRef="#af19"><personName><givenNames>Sue</givenNames><familyName>Thomas</familyName></personName></creator><creator xml:id="au20" creatorRole="author" affiliationRef="#af20"><personName><givenNames>David</givenNames><familyName>Rye</familyName></personName></creator><creator xml:id="au21" creatorRole="author" affiliationRef="#af21"><personName><givenNames>Yoshio</givenNames><familyName>Tsuboi</familyName></personName></creator><creator xml:id="au22" creatorRole="author" affiliationRef="#af22"><personName><givenNames>Annette</givenNames><familyName>Hand</familyName></personName></creator><creator xml:id="au23" creatorRole="author" affiliationRef="#af23 #af24"><personName><givenNames>Anthony H.V.</givenNames><familyName>Schapira</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>National Parkinson Foundation Centre of Excellence, Kings College Hospital, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="GB" type="organization"><unparsedAffiliation>Department of Neurology, University Hospital Lewisham, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="GB" type="organization"><unparsedAffiliation>Kings College, Institute of Psychiatry, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="ES" type="organization"><unparsedAffiliation>Unit of Neuroepidemiology, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="GB" type="organization"><unparsedAffiliation>Department of Psychology, Institute of Psychiatry, King's College London, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Medical College of Georgia, USA</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="IT" type="organization"><unparsedAffiliation>Department of Neurology, IRCCS San Raffaele, Pisana, Roma, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="DE" type="organization"><unparsedAffiliation>Department of Neurology, Klinikum‐Bremerhaven Reinkenheide, Bremerhaven, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</unparsedAffiliation></affiliation><affiliation xml:id="af10" countryCode="JP" type="organization"><unparsedAffiliation>Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan</unparsedAffiliation></affiliation><affiliation xml:id="af11" countryCode="GB" type="organization"><unparsedAffiliation>Medicine for the Elderly, Southern General Hospital, Glasgow, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af12" countryCode="GB" type="organization"><unparsedAffiliation>Medicine for Care of Elderly, Camborne‐Redruth Hospital, Redruth, Cornwall, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af13" countryCode="IT" type="organization"><unparsedAffiliation>Department of Neurological Sciences, University of Napoli, Napoli, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af14" countryCode="IL" type="organization"><unparsedAffiliation>Department of Neurology, Assaf Harofeh Medical Center, School of Medicine, Tel‐Aviv University, Zerifin, Israel</unparsedAffiliation></affiliation><affiliation xml:id="af15" countryCode="GB" type="organization"><unparsedAffiliation>Research and Development Department, The UK Parkinson's Disease Society, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af16" countryCode="GB" type="organization"><unparsedAffiliation>Department of Neurology, University Hospital Lewisham, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af17" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, The Mount Sinai School of Medicine, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af18" countryCode="GB" type="organization"><unparsedAffiliation>Lane Fox Sleep Centre, St. Thomas' Hospital, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af19" countryCode="GB" type="organization"><unparsedAffiliation>Policy Advice, Royal College of Nursing, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af20" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Emory University, Atlanta, Georgia, USA</unparsedAffiliation></affiliation><affiliation xml:id="af21" countryCode="US" type="organization"><unparsedAffiliation>Fifth Department of Internal Medicine, Fukuoka University, Fukuoka, Japan</unparsedAffiliation></affiliation><affiliation xml:id="af22" countryCode="GB" type="organization"><unparsedAffiliation>Department of Medicine, North Tyneside General Hospital, North Shields, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af23" countryCode="GB" type="organization"><unparsedAffiliation>Department of Clinical Neuroscience, Royal Free Hospital Medical School, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af24" countryCode="GB" type="organization"><unparsedAffiliation>National Hospital for Neurology and Neurosurgery, London, United Kingdom</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">PD</keyword><keyword xml:id="kwd2">non‐motor</keyword><keyword xml:id="kwd3">UPDRS</keyword><keyword xml:id="kwd4">questionnaire</keyword><keyword xml:id="kwd5">quality of life</keyword></keywordGroup><fundingInfo><fundingAgency>PDNMG</fundingAgency></fundingInfo><fundingInfo><fundingAgency>UK Parkinson's Disease Society</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Pfizer</fundingAgency></fundingInfo><fundingInfo><fundingAgency>GSK</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Boehringer‐Ingelheim</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Britannia Pharamaceuticals</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Non‐motor symptoms (NMS) in Parkinson's disease (PD) are common, significantly reduce quality of life and at present there is no validated clinical tool to assess the progress or potential response to treatment of NMS. A new 30‐item scale for the assessment of NMS in PD (NMSS) was developed. NMSS contains nine dimensions: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems, attention/memory, gastrointestinal, urinary, sexual function, and miscellany. The metric attributes of this instrument were analyzed. Data from 242 patients mean age 67.2 ± 11 years, duration of disease 6.4 ± 6 years, and 57.3% male across all stages of PD were collected from the centers in Europe, USA, and Japan. The mean NMSS score was 56.5 ± 40.7, (range: 0–243) and only one declared no NMS. The scale provided 99.2% complete data for the analysis with the total score being free of floor and ceiling effect. Satisfactory scaling assumptions (multitrait scaling success rate >95% for all domains except miscellany) and internal consistency were reported for most of the domains (mean α, 0.61). Factor analysis supported the <i>a prori</i> nine domain structure (63% of the variance) while a small test–retest study showed satisfactory reproducibility (ICC > 0.80) for all domains except cardiovascular (ICC = 0.45). In terms of validity, the scale showed modest association with indicators of motor symptom severity and disease progression but a high correlation with other measures of NMS (NMSQuest) and health‐related quality of life measure (PDQ‐8) (both, rS = 0.70). In conclusion, NMSS can be used to assess the frequency and severity of NMS in PD patients across all stages in conjunction with the recently validated non‐motor questionnaire. © 2007 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Non‐Motor Symptoms and PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study</title></titleInfo><name type="personal"><namePart type="given">Kallol Ray</namePart><namePart type="family">Chaudhuri</namePart><affiliation>National Parkinson Foundation Centre of Excellence, Kings College Hospital, London, United Kingdom</affiliation><affiliation>Department of Neurology, University Hospital Lewisham, London, United Kingdom</affiliation><affiliation>Kings College, Institute of Psychiatry, London, United Kingdom</affiliation><description>Correspondence: NPF Centre of Excellence, Movement Disorders Unit, 9th Floor Ruskin Wing, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pablo</namePart><namePart type="family">Martinez‐Martin</namePart><affiliation>Unit of Neuroepidemiology, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Richard G.</namePart><namePart type="family">Brown</namePart><affiliation>Department of Psychology, Institute of Psychiatry, King's College London, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kapil</namePart><namePart type="family">Sethi</namePart><affiliation>Department of Neurology, Medical College of Georgia, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fabrizio</namePart><namePart type="family">Stocchi</namePart><affiliation>Department of Neurology, IRCCS San Raffaele, Pisana, Roma, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Per</namePart><namePart type="family">Odin</namePart><affiliation>Department of Neurology, Klinikum‐Bremerhaven Reinkenheide, Bremerhaven, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">William</namePart><namePart type="family">Ondo</namePart><affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kazuo</namePart><namePart type="family">Abe</namePart><affiliation>Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Graeme</namePart><namePart type="family">MacPhee</namePart><affiliation>Medicine for the Elderly, Southern General Hospital, Glasgow, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Doug</namePart><namePart type="family">MacMahon</namePart><affiliation>Medicine for Care of Elderly, Camborne‐Redruth Hospital, Redruth, Cornwall, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paolo</namePart><namePart type="family">Barone</namePart><affiliation>Department of Neurological Sciences, University of Napoli, Napoli, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Martin</namePart><namePart type="family">Rabey</namePart><affiliation>Department of Neurology, Assaf Harofeh Medical Center, School of Medicine, Tel‐Aviv University, Zerifin, Israel</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alison</namePart><namePart type="family">Forbes</namePart><affiliation>National Parkinson Foundation Centre of Excellence, Kings College Hospital, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kieran</namePart><namePart type="family">Breen</namePart><affiliation>Research and Development Department, The UK Parkinson's Disease Society, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Susanne</namePart><namePart type="family">Tluk</namePart><affiliation>Department of Neurology, University Hospital Lewisham, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yogini</namePart><namePart type="family">Naidu</namePart><affiliation>Department of Neurology, University Hospital Lewisham, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Warren</namePart><namePart type="family">Olanow</namePart><affiliation>Department of Neurology, The Mount Sinai School of Medicine, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Adrian J.</namePart><namePart type="family">Williams</namePart><affiliation>Lane Fox Sleep Centre, St. Thomas' Hospital, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sue</namePart><namePart type="family">Thomas</namePart><affiliation>Policy Advice, Royal College of Nursing, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David</namePart><namePart type="family">Rye</namePart><affiliation>Department of Neurology, Emory University, Atlanta, Georgia, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yoshio</namePart><namePart type="family">Tsuboi</namePart><affiliation>Fifth Department of Internal Medicine, Fukuoka University, Fukuoka, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Annette</namePart><namePart type="family">Hand</namePart><affiliation>Department of Medicine, North Tyneside General Hospital, North Shields, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anthony H.V.</namePart><namePart type="family">Schapira</namePart><affiliation>Department of Clinical Neuroscience, Royal Free Hospital Medical School, London, United Kingdom</affiliation><affiliation>National Hospital for Neurology and Neurosurgery, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-10-15</dateIssued><dateCaptured encoding="w3cdtf">2007-03-06</dateCaptured><dateValid encoding="w3cdtf">2007-04-24</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">5</extent><extent unit="references">46</extent><extent unit="words">6780</extent></physicalDescription><abstract lang="en">Non‐motor symptoms (NMS) in Parkinson's disease (PD) are common, significantly reduce quality of life and at present there is no validated clinical tool to assess the progress or potential response to treatment of NMS. A new 30‐item scale for the assessment of NMS in PD (NMSS) was developed. NMSS contains nine dimensions: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems, attention/memory, gastrointestinal, urinary, sexual function, and miscellany. The metric attributes of this instrument were analyzed. Data from 242 patients mean age 67.2 ± 11 years, duration of disease 6.4 ± 6 years, and 57.3% male across all stages of PD were collected from the centers in Europe, USA, and Japan. The mean NMSS score was 56.5 ± 40.7, (range: 0–243) and only one declared no NMS. The scale provided 99.2% complete data for the analysis with the total score being free of floor and ceiling effect. Satisfactory scaling assumptions (multitrait scaling success rate >95% for all domains except miscellany) and internal consistency were reported for most of the domains (mean α, 0.61). Factor analysis supported the a prori nine domain structure (63% of the variance) while a small test–retest study showed satisfactory reproducibility (ICC > 0.80) for all domains except cardiovascular (ICC = 0.45). In terms of validity, the scale showed modest association with indicators of motor symptom severity and disease progression but a high correlation with other measures of NMS (NMSQuest) and health‐related quality of life measure (PDQ‐8) (both, rS = 0.70). In conclusion, NMSS can be used to assess the frequency and severity of NMS in PD patients across all stages in conjunction with the recently validated non‐motor questionnaire. © 2007 Movement Disorder Society</abstract><note type="funding">PDNMG</note><note type="funding">UK Parkinson's Disease Society</note><note type="funding">Pfizer</note><note type="funding">GSK</note><note type="funding">Boehringer‐Ingelheim</note><note type="funding">Britannia Pharamaceuticals</note><subject lang="en"><genre>Keywords</genre><topic>PD</topic><topic>non‐motor</topic><topic>UPDRS</topic><topic>questionnaire</topic><topic>quality of life</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>13</number></detail><extent unit="pages"><start>1901</start><end>1911</end><total>11</total></extent></part></relatedItem><identifier type="istex">0B767526089E03D8DB1524ADD54446FEA89E3A74</identifier><identifier type="DOI">10.1002/mds.21596</identifier><identifier type="ArticleID">MDS21596</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001318 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001318 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:0B767526089E03D8DB1524ADD54446FEA89E3A74
|texte= The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study
}}
| This area was generated with Dilib version V0.6.23. |  |